Trial Profile
Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; Severe acute respiratory syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms SARCOVID
- 09 Nov 2021 Primary endpoint (Median (IQR) change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation) has not been met as per results presented at the ACR Convergence 2021
- 09 Nov 2021 Primary endpoint (Death) has not been met as per results presented at the ACR Convergence 2021
- 09 Nov 2021 Primary endpoint (Duration of hospitalisation (days)) has not been met as per results presented at the ACR Convergence 2021